HengRui
恒瑞医药
Founded in 1970, this pharmaceutical and healthcare enterprise is engaged in medical innovation, high-quality drug research and development, production, and promotion. It is a well-known Chinese player in areas such as oncology, surgical medicine, autoimmune diseases, metabolic disorders, cardiovascular diseases, etc. It conducts new drug research and supplies contrast agents. The company has established research and development centers or branches in locations including Lianyungang, Shanghai, Chengdu, the United States, and Europe.
Over the years, this pharmaceutical company has been deeply rooted in China while aiming at the global market. It focuses on the health industry, concentrates on cutting-edge fields, and overcomes challenges to promote the high-quality development of the pharmaceutical industry. The company places technology innovation as its primary development strategy, maintaining high-intensity investment in research and development. In the past decade, the company’s accumulated R&D investment has reached 23.8 billion yuan, with 6.203 billion yuan invested in 2021 alone. R&D investment accounted for 23.95% of the revenue, ranking at the forefront of the industry. The company has established research and development centers or branches in locations including Lianyungang, Shanghai, Chengdu, the United States, and Europe, forming a global R&D team of over 5,000 professionals with large-scale, specialization, and comprehensive capabilities. Currently, the company has gained approval for marketing 12 innovative drugs, including Ruriforam, Hequforbpa, and Carilizumab. The introduction of the Class 1 new drug, Linpulise, has also been approved for marketing. This is one of the early innovative drugs from external collaborations to gain approval for marketing. Additionally, over 60 innovative drugs are in clinical development, and more than 260 clinical trials are being conducted globally. The company’s rich R&D pipeline spans various therapeutic areas, not only in its traditional strength of oncology but also in forward-looking areas like autoimmune diseases, pain management, cardiovascular diseases, and metabolic disorders. The company has established a number of independent intellectual property and internationally advanced new technology platforms, providing a strong foundation for innovative research and development. As of the end of 2022, the company had filed 2,064 invention patents, 583 PCT patents, and possessed 507 domestically authorized invention patents, as well as 618 foreign authorized patents in countries such as Europe, the United States, and Japan.
The company continues to steadily advance internationalization. As of the end of 2021, its products had entered more than 40 countries, and it is accelerating efforts to expand in global markets with a focus on emerging markets. The company adheres to a dual emphasis on independent research and development and open collaboration, enhancing international cooperation on the foundation of endogenous development. Through partnerships with American and Korean companies, it has licensed innovative drugs with independent intellectual property rights such as SHR2554, Carilizumab, and SHR0302 to the international market. Furthermore, the company has obtained more than 20 registered approvals for injection, oral, and inhalation anesthesia formulations in Europe, the United States, and Japan, thereby improving drug accessibility for patients in different regions globally.
With perseverance and a forward-looking spirit, the company looks towards a prosperous future. In its future development, it will continue to adhere to the mission of “technology-based, creating a healthy life for humanity,” and the vision of “dedicating to innovation, building a multinational pharmaceutical group.” It will accelerate technological innovation, strive to develop more new and effective drugs, benefit patients, and better serve a healthy life.
